A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
Infection, Human Immunodeficiency Virus
About this trial
This is an interventional treatment trial for Infection, Human Immunodeficiency Virus focused on measuring antiretroviral therapy naive subjects, fosamprenavir, HIV-1, protease inhibitor, pro-drug, antiretroviral therapy, LEXIVA, AGENERASE, GW433908, amprenavir
Eligibility Criteria
Inclusion Criteria: Male or non-pregnant/non-lactating females >/=13 years of age (or >/= 18 years of age according to local requirements). Received fosamprenavir through prior participation in APV20001, APV30002, APV30003 or PRO30017 or have participated in APV30001 or other studies as deemed appropriate by the project team. Exclusion Criteria: Permanent discontinuation of GW433908 in a previous study due to intolerance. An active CDC Class C Event. Any condition which, in the opinion of the investigator, would preclude a subject from participation.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site